Featured Publications
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatientsUrine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 2019, 4: e127456. PMID: 31092735, PMCID: PMC6542610, DOI: 10.1172/jci.insight.127456.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney diseasePrebiopsy diagnosisKidney biopsyKidney diseaseIL-9AIN diagnosisUrine TNFInterstitial nephritisSpecific T cell subsetsAcute tubular injuryDiabetic kidney diseaseIL-9 levelsTNF-α levelsT cell subsetsAddition of biomarkersPlasma cytokinesCytokine levelsTubular injuryHighest quartileMultivariable analysisCell subsetsUrinary TNFBlood eosinophilsGlomerular diseaseDevelopment and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogenMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activationUrine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data
2024
Novel Biomarkers and Imaging Tests for AKI Diagnosis in Patients with Cancer.
Mistry K, Sadarangani S, Moreno D, Mejia S, Moledina D, Sise M. Novel Biomarkers and Imaging Tests for AKI Diagnosis in Patients with Cancer. Kidney360 2024 PMID: 39575585, DOI: 10.34067/kid.0000000660.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute kidney injuryEtiology of acute kidney injuryNeutrophil gelatinase-associated lipocalinImmune checkpoint inhibitorsAcute interstitial nephritisPatients treated with immune checkpoint inhibitorsDiagnosis of acute interstitial nephritisPersistent acute kidney injuryDiagnosis of acute kidney injuryAcute kidney injury diagnosisTumor necrosis factor-alphaKidney injury molecule 1Acute tubular injuryGroup of patientsPre-renal azotemiaNecrosis factor-alphaNon-invasive urineUrine protein quantificationUnmet clinical needNon-invasive diagnostic toolC-X-CCheckpoint inhibitorsUrinary obstructionCisplatin administrationBlood-based biomarkers
2019
Differentiating Acute Interstitial Nephritis from Acute Tubular Injury: A Challenge for Clinicians
Moledina DG, Parikh CR. Differentiating Acute Interstitial Nephritis from Acute Tubular Injury: A Challenge for Clinicians. Nephron 2019, 143: 211-216. PMID: 31203275, PMCID: PMC6821567, DOI: 10.1159/000501207.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute interstitial nephritisAcute tubular injuryAcute kidney injuryUrine TNFTubular injuryInterstitial nephritisClinical featuresHistological diagnosisInterleukin-9Novel biomarkersClinical practiceChronic kidney diseaseProspective cohort studyHigh-risk populationDisease-specific therapiesCourse of careImmunosuppressive therapyKidney injuryCohort studyKidney biopsyKidney diseasePlasma levelsKidney fibrosisInter-rater variabilityLaboratory assessment
2016
PPIs and kidney disease: from AIN to CKD
Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. Journal Of Nephrology 2016, 29: 611-616. PMID: 27072818, DOI: 10.1007/s40620-016-0309-2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute interstitial nephritisProton pump inhibitorsChronic kidney diseaseKidney diseaseDrug-induced acute interstitial nephritisExcellent overall safety profileHigher CKD riskSystemic allergic manifestationsAcute kidney injuryAdverse renal eventsGlomerular filtration rateOverall safety profilePopulation-based studyMillions of patientsAIN diagnosisRenal eventsCKD riskKidney injuryAllergic manifestationsInterstitial nephritisMedian timeSafety profileDrug initiationKidney failurePump inhibitors